NEW YORK—The Centers for Therapeutic Innovation, Pfizer Inc.'s network of translational research partnerships, has officially launched in Boston, with Boston University School of Medicine, Beth Israel Deaconess Medical Center, Partners HealthCare, Harvard University, Children's Hospital Boston, Tufts University, Tufts Medical Center and University of Massachusetts Medical School in Worcester. The organizations follow on partnerships that were already announced with academic medical institutions in California and New York City, where two other Centers for Therapeutic Innovation reside.
"We are thrilled that Pfizer has chosen Boston as the location for its newest Center for Therapeutic Innovation—which will also serve as the program's world headquarters," Mass. Governor Deval Patrick said in a press release. "Pfizer's decision to increase its investments in Massachusetts is further confirmation of the kind of world-class expertise our state can offer the life sciences industry."
Pfizer has leased laboratory space at the Center for Life Science in the Longwood Medical Area. Once Pfizer has developed the space, it will serve as the world headquarters for the Centers for Therapeutic Innovation and complement the offices presently located in Cambridge, Mass. Pfizer will co-locate to the new center with its academic medical center partners, and there will be 40 employees at the new headquarters.
"Pfizer has chosen the perfect location for its new Center for Therapeutic Innovation. Boston is leading the life sciences revolution because of the collaboration that happens between our prestigious medical, academic and research institutions," Boston Mayor Thomas M. Menino said in a press release. "The City is committed to supporting this industry because of the critical role drug discovery plays in our society. We couldn't be happier that Pfizer is further expanding its presence in Massachusetts to tap into all that Longwood Medical area has to offer."
Jose Carlos Gutierrez-Ramos, Ph.D, senior vice president and head of BioTherapeutics Research and Development for Pfizer, said in a press release that the Centers consist of "a network of partnerships between Pfizer and academic medical centers that aims to accelerate and transform drug discovery and development." Over the next five years, Pfizer will invest approximately $100 million into the Boston Centers for Therapeutic Innovation, a sum which represents an estimated total of the support for research programs, potential milestone payments to partners based on the success of projects and the leasing and operational costs of the Longwood Medical Area site.
The goal of the Centers for Therapeutic Innovation is to start closing the gap between research and actually getting new drug candidates into clinical trials. The partnerships "allow leading medical and clinical experts to join with Pfizer's highly-skilled scientists and advanced drug development capabilities to speed the translation of innovative science into medicines for patients," said Gutierrez-Ramos in a press release, adding that Pfizer's ultimate goal is to "bridge the gap between scientific discovery and the delivery of promising candidates to the pipeline." Gutierrez-Ramos will oversee all three Centers for Therapeutic Innovation.
"Academic medical centers play an integral role in the early discovery process that leads to drug development," said Eric Buehrens, Interim president and chief executive officer of Boston's Beth Israel Deaconess Medical Center (BIDMC), in a press release. "But moving these discoveries from the laboratory into the clinic has proven to be exceptionally challenging and costly. That's why we're so pleased to be part of this unique collaboration with Pfizer. Through the Centers for Therapeutic Innovation, scientists at BIDMC and throughout Boston will be able to see their research translated into potential therapies that can make a difference to the lives of patients."
"We believe the Centers for Therapeutic Innovation are an industry-leading model of collaboration and innovation," said Anthony Coyle, Ph.D., vice president - Pfizer Centers for Therapeutic Innovation, in a press release. "Boston, with its wealth of scientific and medical expertise, is well-suited to serve as headquarters for CTI. We are excited to work with these outstanding academic medical institutions with the objective of developing the next generation of medicines."
SOURCE: Pfizer press release
"We are thrilled that Pfizer has chosen Boston as the location for its newest Center for Therapeutic Innovation—which will also serve as the program's world headquarters," Mass. Governor Deval Patrick said in a press release. "Pfizer's decision to increase its investments in Massachusetts is further confirmation of the kind of world-class expertise our state can offer the life sciences industry."
Pfizer has leased laboratory space at the Center for Life Science in the Longwood Medical Area. Once Pfizer has developed the space, it will serve as the world headquarters for the Centers for Therapeutic Innovation and complement the offices presently located in Cambridge, Mass. Pfizer will co-locate to the new center with its academic medical center partners, and there will be 40 employees at the new headquarters.
"Pfizer has chosen the perfect location for its new Center for Therapeutic Innovation. Boston is leading the life sciences revolution because of the collaboration that happens between our prestigious medical, academic and research institutions," Boston Mayor Thomas M. Menino said in a press release. "The City is committed to supporting this industry because of the critical role drug discovery plays in our society. We couldn't be happier that Pfizer is further expanding its presence in Massachusetts to tap into all that Longwood Medical area has to offer."
Jose Carlos Gutierrez-Ramos, Ph.D, senior vice president and head of BioTherapeutics Research and Development for Pfizer, said in a press release that the Centers consist of "a network of partnerships between Pfizer and academic medical centers that aims to accelerate and transform drug discovery and development." Over the next five years, Pfizer will invest approximately $100 million into the Boston Centers for Therapeutic Innovation, a sum which represents an estimated total of the support for research programs, potential milestone payments to partners based on the success of projects and the leasing and operational costs of the Longwood Medical Area site.
The goal of the Centers for Therapeutic Innovation is to start closing the gap between research and actually getting new drug candidates into clinical trials. The partnerships "allow leading medical and clinical experts to join with Pfizer's highly-skilled scientists and advanced drug development capabilities to speed the translation of innovative science into medicines for patients," said Gutierrez-Ramos in a press release, adding that Pfizer's ultimate goal is to "bridge the gap between scientific discovery and the delivery of promising candidates to the pipeline." Gutierrez-Ramos will oversee all three Centers for Therapeutic Innovation.
"Academic medical centers play an integral role in the early discovery process that leads to drug development," said Eric Buehrens, Interim president and chief executive officer of Boston's Beth Israel Deaconess Medical Center (BIDMC), in a press release. "But moving these discoveries from the laboratory into the clinic has proven to be exceptionally challenging and costly. That's why we're so pleased to be part of this unique collaboration with Pfizer. Through the Centers for Therapeutic Innovation, scientists at BIDMC and throughout Boston will be able to see their research translated into potential therapies that can make a difference to the lives of patients."
"We believe the Centers for Therapeutic Innovation are an industry-leading model of collaboration and innovation," said Anthony Coyle, Ph.D., vice president - Pfizer Centers for Therapeutic Innovation, in a press release. "Boston, with its wealth of scientific and medical expertise, is well-suited to serve as headquarters for CTI. We are excited to work with these outstanding academic medical institutions with the objective of developing the next generation of medicines."
SOURCE: Pfizer press release
